News & Blog

Tag Archives: GBM

NBTS Brain Tumor Clinical Trials Report: Q4 2021

It can be hard to keep track of new clinical trial opportunities opening across the United States, especially as we continue to navigate the public health crisis created by the coronavirus (COVID-19). There are many clinical trials actively enrolling patients, and this report provides a summary of the studies that have recently opened or started […]

Widely-available Drug May Benefit Glioblastoma Treatment

Based on data from NBTS’s Defeat GBM Research Collaborative and with support from the Sharpe family, Dr. Paul Mischel (Stanford University) and his laboratory team found that the antidepressant drug, fluoxetine (common brand name: Prozac), potently targets tumor metabolism and inhibits epidermal growth factor (EGFR) signaling, triggering the killing of glioblastoma (GBM) cells. Dr. Mischel’s […]

Years of scientific progress lead to hope for glioblastoma patient

With funding from the National Brain Tumor Society, Clark C. Chen, MD, PhD of the University of Minnesota is ready to start a clinical trial for a drug that is already showing early promise for a glioblastoma patient. The following blog, which has been lightly edited, was originally published on the University of Minnesota’s Neurosurgery […]

Share